Exoplanets that cling too tightly to their stars trigger their own doom: 'This is a completely new phenomenon'
Some planets take the expression "you're your own worst enemy" to the extreme. At least, that's what astronomers found when they recently discovered a doomed planet clinging to its parent star so tightly that it's triggering explosive outbursts and destroying itself.
The clingy, self-destructive extrasolar planet, or "exoplanet," in question is called HIP 67522 b. It orbits a young, 17 million-year-old star so closely that one of its years lasts just one Earth week.
Considering our middle-aged star, the sun, is 4.6 billion years old, the stellar parent of this clingy exoplanet (called HIP 67522) is a relative infant. This means it is bursting with energy.
Since the mid-1990s, when the first exoplanets were discovered, astronomers have pondered whether exoplanets can orbit their stars closely enough that stellar magnetic fields are impacted. Over 5,000 exoplanet discoveries later and astronomers still hadn't found the answer.
That is, until now.
"We hadn't seen any systems like HIP 67522 before; when the planet was found, it was the youngest planet known to be orbiting its host star in less than 10 days," team leader and Netherlands Institute for Radio Astronomy (ASTRON) researcher Ekaterina Ilin said in a statement. "I have a million questions because this is a completely new phenomenon, so the details are still not clear."
The team discovered HIP 67522 while using NASA's exoplanet hunting spacecraft TESS (Transiting Exoplanet Survey Satellite) to survey flaring stars.
TESS discovered some interesting characteristics of HIP 67522, prompting a follow-up investigation with the European Space Agency (ESA) mission Cheops (Characterizing Exoplanet Satellite).
"We quickly requested observing time with Cheops, which can target individual stars on demand, ultra precisely," Ilin said. "With Cheops, we saw more flares, taking the total count to 15, almost all coming in our direction as the planet transited in front of the star as seen from Earth."
Ilin and colleagues discovered that the stellar flares being thrown out by HIP 67522 occur when its clingy planet passes in front of, or "transits," the star. That means these flares are very likely triggered by the planet itself. The team theorizes this occurs because HIP 67522 b is so close to its star that it exerts a magnetic influence on the star.
As the planet whips around the star, it gathers energy, which is redirected as waves rippling down the star's magnetic field lines. When a wave hits the stellar surface, a massive flare is triggered.
"The planet seems to be triggering particularly energetic flares," Ilin explained. "The waves it sends along the star's magnetic field lines kick off flares at specific moments. But the energy of the flares is much higher than the energy of the waves.
"We think that the waves are setting off explosions that are waiting to happen."
This is therefore the first hard evidence that planets can influence the behavior of their stars.
HIP 67522 b isn't just triggering flares facing nowhere, though. These induced flares are directed toward the world itself. In particular, it is bombarded with around six times the radiation a planet at this orbital distance usually would experience.
As you might imagine, this bombardment spells doom for HIP 67522 b. The planet is currently around the size of Jupiter, but it has around the density of candy floss.
The planet's wispy outer layers are being stripped away by harsh radiation, causing the planet to lose even the little mass it has. Over the next 100 million years, HIP 67522 b is expected to drop from the size of Jupiter to around the size of Neptune. The team doesn't actually quite know how extreme the damage these self-inflicted flares could be for HIP 67522 b.
Related Stories:
— 'Vampire stars' explode after eating too much — AI could help reveal why
—Could nearby stars have habitable exoplanets? NASA's Chandra X-ray Observatory hopes to find out
—The James Webb Space Telescope has discovered its 1st exoplanet and snapped its picture (image)
"There are two things that I think are most important to do now. The first is to follow up in different wavelengths to find out what kind of energy is being released in these flares — for example, ultraviolet and X-rays are especially bad news for the exoplanet," Ilin said. "The second is to find and study other similar star-planet systems; by moving from a single case to a group of 10 to 100 systems, theoretical astronomers will have something to work with."
The team's research was published on Wednesday (July 2) in the journal Nature.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Tech giant OpenAI signs deal with government to boost efficiency in public services
OpenAI has signed a deal with the government to use artificial intelligence (AI) in an effort to increase department efficiency. The new partnership will involve the ChatGPT creator exploring how AI can be used in areas such as education, justice, defence and security to make them "more efficient and effective". They will also explore investing in British AI infrastructure, such as data centres. Politics latest: Ministers want OpenAI to identify how advanced AI models could help improve services used by the public. Technology Secretary Peter Kyle said: "AI will be fundamental in driving the change we need to see across the country - whether that's in fixing the NHS, breaking down barriers to opportunity or driving economic growth. "This can't be achieved without companies like OpenAI, who are driving this revolution forward internationally. This partnership will see more of their work taking place in the UK." In an attempt to become a global AI hub, the government previously set out plans to invest £1 billion in infrastructure for AI development, with the plan to increase capacity 20-fold over the next five years. However, the creative industries have criticised their commitment to AI, which they say could be at the detriment of their jobs. Concerns around the amount of water needed to cool data centres and the amount of energy AI uses have also been raised as the government tries to tackle water shortages, pollution, and high energy bills. Read more:The wealth tax options Reeves could take to ease her fiscal bindUk gives final go-ahead to £38bn Sizewell C nuclear plant OpenAI, headed up by the American Sam Altman, also has plans to increase the size of its London office, which was the company's first international location two years ago. The government hopes the partnership will mean "world-changing" AI tech is developed in the UK. OpenAI will look to invest in and support AI "growth zones" across the UK, which will receive funding, the government said. Mr Altman said: "AI is a core technology for nation building that will transform economies and deliver growth. "Britain has a strong legacy of scientific leadership and its Government was one of the first to recognise the potential of AI through its AI Opportunities Action Plan. "Now, it's time to deliver on the plan's goals by turning ambition to action and delivering prosperity for all." The civil service already uses ChatGPT in its AI assistant, "Humphrey", to speed up admin tasks.
Yahoo
10 minutes ago
- Yahoo
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present full data from the prespecified Alzheimer's Disease (AD) biomarker analyses in the BROADWAY clinical trial (NCT05142722) in a late-breaking oral presentation at the Alzheimer's Association International Conference (AAIC), being held July 30, 2025 in Toronto, Canada. Details of the presentation are as follows: Presentation Title: Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with Cardiovascular DiseaseSession Title: Developing Topics on Innovative Therapeutic ApproachesPresentation Date and Time: Wednesday, July 30, 2025, 8:21-8:28 AM ETPresenter: Philip Scheltens M.D., Room 718 Conference Call and Webcast Information NewAmsterdam will host a live webcast and conference call at 10:00 a.m. ET on July 30, 2025 to review the full AD biomarker data presented at AAIC. The call will include remarks from featured speakers including: Philip Scheltens, M.D., Ph.D., professor of Neurology at the Vrije Universiteit Amsterdam and partner and head of EQT Life Sciences Dementia Fund; Kellyann Niotis, M.D., director of Parkinson's and Lewy Body Dementia Research at The Institute for Neurogenerative Diseases - Parkinson's and Alzheimer's Research Education Foundation; and Nathaniel Chin, M.D., medical director and Clinical Core Co-Leader for the Wisconsin Alzheimer's Disease Research Center (ADRC) and medical director for the Wisconsin Registry for Alzheimer's Prevention (WRAP). To access the live webcast, participants may register here. The live webcast will be available under the 'Events & Presentations' section of the Investor Relations page of the Company's website at To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam's website following the live event. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactReal Chemistry on behalf of NewAmsterdamChristian EdgingtonP: 1-513-310-6410cedgington@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
11 minutes ago
- Medscape
Early Menopause Blues: Not Just About Hormones
TOPLINE: Among women with premature ovarian insufficiency, 29.9% experienced depressive symptoms, with younger age at diagnosis, severe menopausal symptoms, and lack of emotional support being key risk factors. Oestradiol levels and the use of hormone therapy were not significantly associated with the risk for depression, underscoring the role of psychosocial factors. METHODOLOGY: Researchers in the Netherlands conducted an exploratory cross-sectional study of 345 women with premature ovarian insufficiency (median age at diagnosis, 32 years) to identify factors associated with the development of depression in this population. The diagnostic criteria for premature ovarian insufficiency included oligo/amenorrhoea for at least 4 months and an elevated follicle-stimulating hormone level (> 25 IU/L) on two occasions at least 4 weeks apart. Validated questionnaires were used to measure the severity of depressive symptoms, frequency and severity of menopausal symptoms, impact of infertility on various aspects of life, and level of emotional support. Clinical evaluations included recording vital signs and BMI; running a blood panel for lipids and thyroid function; and measuring luteinising hormone, follicle‐stimulating hormone, oestradiol, and progesterone levels. TAKEAWAY: Among the 345 patients, 29.9% reported depressive symptoms and 70.1% did not. Although 42.3% of women were using oestrogen plus progestogen therapy at baseline, no significant difference in depressive symptoms was observed between those receiving and not receiving it (P = .89); oestradiol levels and the receipt of hormone therapy were not associated with depressive symptoms in this study. Severe menopausal symptoms (odds ratio [OR], 1.13; P < .001), lower emotional support (OR, 0.86; P < .001), and younger age at diagnosis (OR, 0.95; P = .01) were each associated with higher odds of depressive symptoms, whereas genetic aetiology was associated with lower odds (OR, 0.10; P = .04). Among women experiencing fertility-related grief, a lower quality of life related to fertility issues was also associated with depressive symptoms. IN PRACTICE: "Our findings underline the need for comprehensive assessment and management of menopausal symptoms, including psychosocial and sexual well-being, in women with POI [premature ovarian insufficiency]. Addressing the psychological impact of POI, including the loss of fertility, is probably crucial in preventing or mitigating depressive symptoms," the authors wrote. SOURCE: This study was led by Charissa van Zwol-Janssens, MD, Division of Reproductive Endocrinology and Infertility, Erasmus MC, Rotterdam, the Netherlands. It was published online on July 15, 2025, in Menopause. LIMITATIONS: The observational design of the study prevented causal inferences between the identified risk factors and depression. The evaluation of symptoms at only one timepoint precluded examining trends over time or identifying at ‐ risk individuals. Moreover, enrolling participants from a single centre may have affected the generalisability of the results. DISCLOSURES: This study did not receive any funding. Some authors reported receiving research grants and fees for consultancy or presentations from various organisations, including pharmaceutical and healthcare companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.